{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:08:45Z","timestamp":1783976925939,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81371852"],"award-info":[{"award-number":["81371852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573676"],"award-info":[{"award-number":["81573676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81721002"],"award-info":[{"award-number":["81721002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National 13th Five-Year Special Grand Project for Infectious Diseases","award":["2017ZX10302201-001"],"award-info":[{"award-number":["2017ZX10302201-001"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.antiviral.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T18:38:56Z","timestamp":1523039936000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Hepatitis B virus rtA181T\/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T\/sW172* mutation"],"prefix":"10.1016","volume":"154","author":[{"given":"Li","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinman","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heling","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.04.003_bib1","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1128\/JVI.00635-14","article-title":"The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene","volume":"88","author":"Ahn","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.003_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2007.06.011","article-title":"Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials","volume":"47","author":"Borroto-Esoda","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.04.003_bib3","first-page":"881","article-title":"The guidelines of prevention and treatment for chronic hepatitis B","volume":"13","author":"Chinese Society of Hepatology","year":"2005","journal-title":"Zhonghua Gan Zang Bing Za Zhi Chin. J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.04.003_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1743-422X-9-280","article-title":"Biological characteristics of the rtA181T\/sW172* mutant strain of Hepatitis B virus in animal model","volume":"9","author":"Dai","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.04.003_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","article-title":"Characterization of novel entecavir resistance mutations","volume":"63","author":"Hayashi","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.04.003_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2893.2010.01301.x","article-title":"Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern","volume":"18","author":"Inoue","year":"2010","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2018.04.003_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2012.02.003","article-title":"The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation","volume":"54","author":"Ji","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.04.003_bib9","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1038\/oncsis.2016.77","article-title":"Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S\/S gene with the sW172* mutation","volume":"5","author":"Lai","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.antiviral.2018.04.003_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"issue":"1 Suppl. l","key":"10.1016\/j.antiviral.2018.04.003_bib11","article-title":"Identification of a triple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"66","author":"Lee","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.003_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12072-008-9048-3","article-title":"Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure","volume":"2","author":"Locarnini","year":"2008","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2018.04.003_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jvh.12298","article-title":"The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil","volume":"22","author":"Liu","year":"2015","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2018.04.003_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.003_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.003_bib16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","article-title":"Hepatitis B virus PreS\/S gene variants: pathobiology and clinical implications","volume":"61","author":"Pollicino","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.04.003_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.04.003_bib18","doi-asserted-by":"crossref","first-page":"61719","DOI":"10.18632\/oncotarget.18682","article-title":"Additional N-glycosylation mutation in the major hydrophilic region of hepatitis B virus S gene is a risk indicator for hepatocellular carcinoma occurrence in patients with coexistence of HBsAg\/anti-HBs","volume":"8","author":"Qiao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.antiviral.2018.04.003_bib19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2893.2009.01254.x","article-title":"Hepatitis B virus genotype and basal core promoter\/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis","volume":"17","author":"Ren","year":"2010","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2018.04.003_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jhep.2017.03.027","article-title":"Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy","volume":"67","author":"Shirvani-Dastgerdi","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.04.003_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2893.2012.01638.x","article-title":"Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovirbased regimen","volume":"20","author":"Svarovskaia","year":"2013","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2018.04.003_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2017.03.008","article-title":"Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: the legacy of lamivudine\/adefovir combination treatment","volume":"143","author":"Vincenti","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.003_bib23","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.003_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.22295","article-title":"The antiviral drug selected hepatitis B virus rtA181T\/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound","volume":"48","author":"Warner","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.003_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3851\/IMP1552","article-title":"Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide\/nucleoside analogue therapy","volume":"15","author":"Yeh","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.04.003_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7883\/yoken.JJID.2015.359","article-title":"Possible involvement of multidrug-resistant hepatitis B virus sW172* truncation variant in the ER stress signaling pathway during hepatocarcinogenesis","volume":"69","author":"Zheng","year":"2016","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.003_bib27","doi-asserted-by":"crossref","first-page":"39260","DOI":"10.1038\/srep39260","article-title":"Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems","volume":"15","author":"Zhou","year":"2016","journal-title":"Sci. Rep."},{"issue":"1 Suppl. l","key":"10.1016\/j.antiviral.2018.04.003_bib28","article-title":"HBV rtL180M+A181C+M204V mutations may lead to entecavir resistance in real-life clinical practice","volume":"66","author":"Zhou","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.04.003_bib29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.04.003_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","article-title":"Reasons to consider earlier treatment of chronic HBV infections","volume":"61","author":"Zoulim","year":"2012","journal-title":"Gut"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:07Z","timestamp":1759062427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217307878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":29,"alternative-id":["S0166354217307878"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus rtA181T\/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T\/sW172* mutation","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}